ICM
ENGNW icon

Ionic Capital Management’s enGene Therapeutics Warrants ENGNW Stock Holding History

Ionic Capital Management’s Portfolio ENGNW Stock Details ENGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,753
Closed -$42.4K – 132
2026
Q1 		$42.4K Buy
+16,753
New +$49.6K ﹤0.01% 144

Other funds holding ENGNW

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return

Ionic Capital Management's ENGNW Position: Q2 2026 in Review

Ionic Capital Management sold out of enGene Therapeutics Warrants (ENGNW) in Q2 2026, closing a stake of 16,753 shares — an estimated $42.4K sold.

Ionic Capital Management first reported a position in ENGNW in Q1 2026 and held it in 1 quarter. The position peaked at $42.4K in Q1 2026. 11 funds tracked by Wall St. Rank hold ENGNW as of Q2 2026.

  • Ionic Capital Management reported no remaining enGene Therapeutics Warrants position as of Q2 2026 after selling out during the quarter.
  • Ionic Capital Management sold 16,753 enGene Therapeutics Warrants shares in Q2 2026, an estimated $42.4K.
  • Ionic Capital Management first reported a position in enGene Therapeutics Warrants in Q1 2026 and held it in 1 quarter.
  • Ionic Capital Management's enGene Therapeutics Warrants position peaked at $42.4K in Q1 2026.
  • 11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q2 2026.

Based on Ionic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.